LivaNova VNS Therapy System for Drug-Resistant Epilepsy Could Save $77,000 Per Patient Over Five Years
Analysis finds overall cost savings far exceed system-related costs
“The ability to improve outcomes while reducing costs is an important area of focus in healthcare today. Our VNS Therapy System achieves this by reducing seizure frequency and by decreasing overall cost of treatment,” said
Approximately one in three patients with epilepsy has DRE. These patients are subject to frequent seizures that require expensive health resources like hospitalizations and emergency department visits. By evaluating more than 1,500 patients in
“Not only did the analysis demonstrate a significant cost savings associated with VNS Therapy treatment in comparison to AED treatment alone, but this savings is based on a very important health outcome – the reduction of seizure frequency,” said
About the RTI Health Solutions Study
This study was conducted by RTI Health Solutions under the direction of
About VNS Therapy for Epilepsy
VNS Therapy is clinically proven safe and effective for the treatment of drug-resistant epilepsy for adults and children. VNS Therapy is designed to prevent seizures before they occur and stop them if they do. It is a unique treatment approach developed for people with drug-resistant epilepsy—a condition that affects one in three people with epilepsy. For more information, visit www.VNSTherapy.com.
INTENDED USE/INDICATIONS –
The VNS Therapy System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients 4 years of age and older with partial onset seizures that are refractory to antiepileptic medications.
Individual results may vary. Common side effects include hoarseness, shortness of breath, sore throat and coughing. To view safety and full prescribing information, visit www.VNSTherapy.com/safety.
LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. LivaNova’s advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. Headquartered in London, LivaNova has a presence in more than 100 countries worldwide. The Company currently employs approximately 4,000 employees. LivaNova operates as two businesses: Cardiac Surgery and Neuromodulation, with operating headquarters in Mirandola (
For more information, please visit www.livanova.com.
Safe Harbor Statement
This news release contains forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements are not historical facts but are based on certain assumptions of management and describe LivaNova’s future plans, strategies and expectations. Forward-looking statements can generally be identified by the use of forward-looking terminology, including, but not limited to, "may," “could,” “seek,” “guidance,” “predict,” “potential,” “likely,” "believe," "will," "expect," "anticipate," "estimate," "plan," "intend," "forecast," or variations of these terms and similar expressions, or the negative of these terms or similar expressions. Forward-looking statements contained in this news release are based on information presently available to
All information in this news release is as of the date of its release.
1 Purser, M.F., Mladsi, D.M., Beckman, A. et al.
LivaNova PLC Media
Deanna Wilke, +1 281-727-2764
Director, Corporate Communications